Brief: Transgene, NEC And BostonGene Announce Strategic Collaboration For Two Ongoing Clinical Trials
Oct 6 (Reuters) - TRANSGENE SA TRNG.PA :
* TRANSGENE, NEC AND BOSTONGENE ANNOUNCE STRATEGIC
COLLABORATION
FOR TWO ONGOING CLINICAL TRIALS FOR PATIENTS WITH OVARIAN AND
HEAD & NECK CANCERS
* COLLABORATION FOR TWO ONGOING PHASE 1 CLINICAL TRIALS OF
TG405
Source text for Eikon: ID:nBwc1x5ZTa
Further company coverage: TRNG.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs